Paul Hudson (AP Images)
Sanofi CEO Paul Hudson’s latest M&A gambit adds new eczema drug in $1.5B buyout. And he’s steering back into a market maelstrom
Around the same time that Sanofi CEO Paul Hudson was engineering a $3.7 billion buyout of Principia to add a late-stage multiple sclerosis drug to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
